Literature DB >> 1071711

Increased renal excretion of arginine-vasopressin during mild hydropenia in young men with mild essential benign hypertension.

A M Khokhar, J D Slater.   

Abstract

1. The rate of renal excretion of arginine-vasopressin was determined during unrestricted fluid intake for 24 h and in response to fluid deprivation for 18 h in nine young men with very mild essential hypertension and compared with that in sixteen normotensive men of similar age. 2. Despite an equivalent osmolar stimulus, excretion of arginine-vasopressin was significantly greater in the reference group than in the reference group. This difference increased progressively with increasing dehydration. 3. We suggest that these findings are mainly due to an increased rate of secretion of arginine-vasopressin in response to mild hydropenia in hypertensive patients and that a moderate increase of release of arginine-vasopressin during periods of fluid deprivation may exert vascular effects and thus influence the perpetuation of hypertension.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1071711     DOI: 10.1042/cs051691s

Source DB:  PubMed          Journal:  Clin Sci Mol Med Suppl        ISSN: 0144-4107


  4 in total

1.  Effect of indapamide on renal plasma flow, glomerular filtration rate and arginine vasopressin in plasma in essential hypertension.

Authors:  E B Pedersen; H Danielsen; E S Spencer
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

2.  [Cardiovascular effect of the antidiuretic hormone arginine vasopressin].

Authors:  W Rascher
Journal:  Klin Wochenschr       Date:  1985-10-01

3.  Regulation of vasopressin release in moderately severe essential hypertension.

Authors:  A Del Bo; M Marabini; A Morganti; A Zanchetti
Journal:  Clin Auton Res       Date:  1991-06       Impact factor: 4.435

4.  Effect of verapamil on renal plasma flow, glomerular filtration rate and plasma angiotensin II, aldosterone and arginine vasopressin in essential hypertension.

Authors:  S S Sørensen; O O Thomsen; H Danielsen; E B Pedersen
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.